CytomX Therapeutics, Inc. (CTMX) — Stock Score Summary

CytomX Therapeutics, Inc. (CTMX) has a MoatMap StockRank of 22/100 based on Quality (43/100), Value (39/100), and Momentum (27/100) factor scores. The current signal is SELL. CytomX Therapeutics is a micro-cap oncology biotech. It is highly speculative, pre-revenue, and lacks the structural cash flows, pricing power, and quality business model required by our investment philosophy.

CytomX Therapeutics, Inc. is a clinical-stage oncology company pioneering the development of Probody therapeutics, a novel class of antibody-based drugs designed for tumor-specific activation. This proprietary technology aims to enhance therapeutic efficacy and reduce systemic toxicity compared to conventional antibodies, offering a potential competitive advantage in the cancer treatment landscape.

Key Financial Metrics

Price$2.98
Market Cap$808M
P/E (Forward)-6.28
Price/Book2.16
Return on Equity-34.3%
Return on Invested Capital-21.3%
Debt/Equity0.89
Gross Margin100.0%
Operating Margin-191.8%
Revenue Growth-79.9%
Free Cash Flow$-42M

CytomX Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is CytomX Therapeutics, Inc.’s (CTMX) StockRank?
MoatMap’s StockRank for CytomX Therapeutics, Inc. (CTMX) is 22/100, with a Sell signal. It is a composite of Quality (43), Value (39), and Momentum (27) factor ranks across MoatMap’s 19,000+ stock universe.
Does CytomX Therapeutics, Inc. have an economic moat?
CytomX Therapeutics, Inc. (CTMX) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is CytomX Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for CytomX Therapeutics, Inc. (CTMX) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is CytomX Therapeutics, Inc. in?
CytomX Therapeutics, Inc. (CTMX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCTMX deep dive reportAI ChampionsHow we score stocksSense-check another stock